Antipsychotics for the treatment of schizophrenia: Likelihood to be helped or harmed, understanding proximal and distal benefits and risks

Expert Review of Neurotherapeutics

Volumn 8, Issue 7, 2008, Pages 1079-1091

  Citrome, Leslie ^a,b   Kantrowitz, Joshua ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Effectiveness; Efficacy; Evidence based medicine; LHH; Likelihood to be helped or harmed; NNH; NNT; Schizophrenia; Tolerability

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; CLOZAPINE; DIPHENHYDRAMINE; GENERIC DRUG; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; CALCULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; METABOLIC DISORDER; MUSCLE RIGIDITY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PARKINSONISM; PHARMACOGENOMICS; QT PROLONGATION; RATING SCALE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; STATISTICAL ANALYSIS; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COMPREHENSION; HUMANS; RISK; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 46949084286     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.7.1079     Document Type: Review

References (71)

1. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment.Dis. 182(11), 631-638 (1994).
2. Citrome L. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad. Med. 112(6), 85-88, 94-96 (2002).
3. Breier A, Buchanan RW, Irish D, Carpenter WT Jr. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp. Community Psych. 44(12), 1145-1149 (1993).
4. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr. Scand. 115(2), 93-100 (2007).
5. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162(3), 441-449 (2005).
6. Peebles SA, Mabe PA, Davidson L, Fricks L, Buckley PF, Fenley G. Recovery and systems transformation for schizophrenia. Psychiatr. Clin. North Am. 30(3), 567-583 (2007).
7. Holt RI, Peveler RC. Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia 49(7), 1467-1476 (2006).
8. Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am. J. Manag. Care 13(Suppl.), 1-12 (2007).
9. Tandon R, Nasrallah HA. Subjecting metaanalyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics at equivalent doses. Arch. Gen. Psychiatry 63(8), 935-937 (2006).
10. Davis JM, Chen N, Glick ID. A metaanalysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60(6), 553-564 (2003).
11. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161(2 Suppl.), 1-56 (2004).
12. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol. Psychiatry 59(11), 990-996 (2005).
13. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J. Clin. Psychiatry 68(12), 1876-1885 (2007).
14. Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int. J. Clin. Pract. 60(8), 933-940 (2006).
15. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005).
16. Gray GE, Pinson LA. Evidence-based medicine and psychiatric practice. Psychiatr. Q 74(4), 387-399 (2003).
17. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr. Scand. 117(6), 412-419 (2008).
18. Citrome L. Show me the evidence: using number needed to treat. South Med. J. 100(9), 881-884 (2007).
19. Gray GE. Concise Guide to Evidence-Based Psychiatry. American Psychiatric Publishing, Inc., Washington, DC, USA (2004).
20. Citrome L. Can you interpret confidence intervals? It's not that difficult. Curr. Psychiatry 6(8), 77-82 (2007).
21. Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. Eval. Health Prof. 25(2), 210-224 (2002).
22. ECDEU Assessment Manual for Psychopharmacology. Revised. US Department of Health, Education, and Welfare, MD, USA (1976).
23. Rosenheck RA, Leslie DL, Busch S, Rofman ES, Sernyak M. Rethinking antipsychotic formulary policy. Schizophr. Bull. 34(2), 375-380 (2008).
24. Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry 63(10), 1069-1072 (2006).
25. McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163(4), 600-610 (2006).
26. Citrome L. Interpreting and applying the CATIE results: with CATIE, context is key, when sorting out phases 1, 1A, 1B, 2E, and 2T Psychiatry MMC 2007, 4(10), 23-29 (2007).
27. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9(11), 984-997 (2004).
28. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med. 12(9), 1016-1022 (2006).
29. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1(2), 133-152 (1987).
30. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47(1), 27-38 (2002).
31. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10(1), 79-104 (2005).
32. Stahl SM. Essential Psychopharmacology. Second Edition. Cambridge University Press, Cambridge, UK (2000).
33. Karagianis J, Rosenbluth M, Tohen M et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr. Med. Res. Opin. 23(10), 2551-2557(2007).
34. Czobor P, Volavka J, Sheitman B et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J. Clin. Psychopharmacol. 22(3), 244-251 (2002).
35. Citrome L. The effectiveness criterion: balancing efficacy against the risks of weight gain. J. Clin. Psychiatry 68(Suppl. 12), 12-17 (2007).
36. Citrome L. Olanzapine: interpreting the label change. Int. J. Clin. Pract. 61(12), 1960-1962 (2007).
37. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin. Proc. 80(8), 1050-1057 (2005).
38. Howes OD, Wheeler MJ, Meaney AM et al. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J. Clin. Psychopharmacol. 25(3), 259-261 (2005).
39. Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophr. Bull. 30(4), 767-779 (2004).
40. Schiavi RC, Stimmel BB, Mandeli J, Schreiner-Engel P, Ghizzani A. Diabetes, psychological function and male sexuality. J. Psychosom. Res. 39(3), 305-314 (1995).
41. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J. Clin. Psychiatry 55(9), 406-413 (1994).
42. Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am. J. Psychiatry 164(3), 415-427 (2007).
43. Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163(4), 611-622 (2006).
44. Citrome L, Jaffe A, Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr. Serv. 58(1), 11 (2007).
45. Citrome L, Jaffe A, Levine J, Lindenmayer JP. Dosing of quetiapine in schizophrenia - how clinical practice differs from registration studies. J. Clin. Psychiatry 66(12), 1512-1516 (2005).
46. Swift RH, Harrigan EP, Cappelleri JP, Kramer D, Chandler LP. Validation of the behavioral activity rating scale (BARS): a novel measure of activity in agitated patients. J. Psychiatr. Res. 36(2), 87-95 (2002).
47. Lindenmayer JP, Brown E, Baker RW et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr. Res. 68(2-3), 331-337 (2004).
48. Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry 59(5), 441-448 (2002).
49. Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence (2008) (In Press).
50. Citrome L. Paliperidone: quo vadis?. Int. J. Clin. Pract. 61(4), 653-662 (2007).
51. Kane J, Canas F, Kramer M et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. 90(1-3), 147-161 (2007).
52. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin. Psychopharmacol. 24(2), 192-208 (2004).
53. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum. Psychopharmacol. 21(8), 529-532 (2006).
54. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry 162(5), 1010-1012 (2005).
55. Citrome L, Holt RI, Zachry WM et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann. Pharmacother. 41(10), 1593-1603 (2007).
56. Tandon R, Belmaker RH, Gattaz WF et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100(1-3), 20-38 (2008).
57. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (9618), 1085-1097 (2008).
58. Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int. J. Clin. Pract. 62(5), 837-840 (2008).
59. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63(10), 1079-1087 (2006).
60. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 12(1), 41-48 (2003).
61. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am. J. Psychiatry 161(4), 700-706 (2004).
62. Ganesan S, Taylor R, Rabheru K, Forbes I, Dumontet J, Procyshyn RM. Antipsychotic polypharmacy does not increase the risk for side effects. Schizophr. Res. 98(1-3), 323-324 (2008).
63. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 51(5), 634-638 (2000).
64. Citrome L. Antiepileptics in the treatment of schizophrenia. In: Antiepileptic drugs to treat psychiatric disorders. McElroy SL, Keck PE, Post RM (Eds). Informa Healthcare, Inc., NY, USA. 11, 187-206 (2008).
65. Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J. Clin. Psychopharmacol. 25(4), 388-391 (2005).
66. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12(8), 707-747 (2007).
67. Bondy B, Spellmann I. Pharmacogenetics of antipsychotics: useful for the clinician? Curr. Opin. Psychiatry 20(2), 126-130 (2007).
68. Lopez-Garcia P, Teresa-Rodriguez J, De Castro P, Landecho I, Zapata R. Association between clozapine-induced agranulocytosis and HLA subtyping. J. Clin. Psychiatry 67(10), 1652-1653 (2006).
69. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet. Genomics 15(4), 195-200 (2005).
70. Center for Evidence-Based Medicine www.cebm.utoronto.ca
71. Ministry of Health and Long-Term Care: Drugs Funded by Ontario Drug Benefit (ODB) Program www.health.gov.on.ca/english/providers/pr ogram/drugs/odbf_eformularyhtml